Characterization of Duvelisib in Patients With Refractory Marginal Zone Lymphoma: Data From the Phase 2 Dynamo Trial
Hematological Oncology - United Kingdom
doi 10.1002/hon.70_2631
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley